Evidence map›Paper›PMID 29118126›Full record

ReviewJournal of virology2018

Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem.

Ralph A Tripp, Ultan F Power, Peter J M Openshaw, Lawrence M Kauvar

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Microbiological and epidemiological features of respiratory syncytial virus.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Ralph A TrippUniversity of Georgia, College of Veterinary Medicine, Department of Infectious Diseases, Athens, Georgia, USA.ORCID http://orcid.org/0000-0002-2924-9956
Ultan F PowerCentre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.
Peter J M OpenshawImperial College London, London, United Kingdom.
Lawrence M KauvarTrellis Bioscience, Menlo Park, California, USA lkauvar@trellisbio.com.
Georgia College & State University · USImperial College London · GBMenlo School · USQueen's University Belfast · GB

Funding

Therapeutic Antibody for RSV IIBR44AI122360 · NIAID · TRELLIS BIOSCIENCE, INC. · PI KAUVAR, LAWRENCE MICHAEL · 2016 to 2021
$5.8M
Biotechnology and Biological Sciences Research Council BB/P004040/1Medical Research Council MR/R005982/1NIAID NIH HHS R44 AI122360Wellcome TrustWellcome Trust 108818/Z/15/A
6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection (LRTI) annually affecting >2 million children in the United States <5 years old. In the elderly (>65 years old), RSV results in ∼175,000 hospitalizations annually in the United States with a worldwide incidence of ∼34 million. There is no approved RSV vaccine, and treatments are limited. Recently, a phase 3 trial in the elderly using a recombinant RSV F protein vaccine failed to meet its efficacy objectives, namely, prevention of moderate-to-severe RSV-associated LRTI and reduced incidence of acute respiratory disease. Moreover, a recent phase 3 trial evaluating suptavumab (REGN2222), an antibody to RSV F protein, did not meet its primary endpoint of preventing medically attended RSV infections in preterm infants. Despite these setbacks, numerous efforts targeting the RSV F protein with vaccines, antibodies, and small molecules continue based on the commercial success of a monoclonal antibody (MAb) against the RSV F protein (palivizumab). As the understanding of RSV biology has improved, the other major coat protein, the RSV G protein, has reemerged as an alternative target reflecting progress in understanding its roles in infecting bronchial epithelial cells and in altering the host immune response. In mouse models, a high-affinity, strain-independent human MAb to the RSV G protein has shown potent direct antiviral activity combined with the alleviation of virus-induced immune system effects that contribute to disease pathology. This MAb, being prepared for clinical trials, provides a qualitatively new approach to managing RSV for populations not eligible for prophylaxis with palivizumab.

Indexed as

Respiratory Syncytial Virus, HumanAnimalsClinical Trials as TopicClinical Trials, Phase III as TopicHumansMicePalivizumabRespiratory Syncytial Virus InfectionsViral Fusion ProteinsViral ProteinsG glycoprotein, Respiratory syncytial virusPalivizumabViral Fusion ProteinsViral ProteinsF proteinG proteinmonoclonal antibodiespalivizumabrespiratory syncytial virusRSV

Identifiers

PMID29118126
PMCPMC5774885
OpenAlexW2767754527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.